Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine ↗

January 04, 2022

On Tuesday, Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MM...

Via Benzinga

2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around? ↗

December 30, 2021

Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv...

Via Benzinga

Cannabis Movers & Shakers: MindMed & Trulieve Management Shake-Ups, Credex Corp & CapStone Bolster Leadership Teams ↗

December 29, 2021

MindMed Announces Management Shake-Ups Mind Medicine Inc. (NASDAQ:

Via Benzinga

Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD ↗

December 24, 2021

All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?

Via Talk Markets

MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder ↗

December 22, 2021

MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic...

Via Benzinga

The Year In Review For Psychedelic Drug Stocks: 2021 ↗

December 21, 2021

2021 was two different

Via Talk Markets

MNMD Stock: The Latest Psychedelic Drug News MindMed Fans Should Watch ↗

December 21, 2021

MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch.

Via InvestorPlace

Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD ↗

December 17, 2021

A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.

Via Talk Markets

MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD ↗

December 17, 2021

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (...

Via Benzinga

Mind Medicine to Study Effect of Time on LSD Microdosing ↗

December 17, 2021

Mind Medicine (NASDAQ: MNMD), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a...

Via Benzinga

Mind Medicine (NASDAQ: MNMD) (NEO: MMED) to Study Effect of Time on LSD Microdosing

December 17, 2021

Via Investor Brand Network

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) to Conduct Study Investigating Effect of Time on LSD Microdosing

December 16, 2021

Via Investor Brand Network

Cannabis Movers & Shakers: HEXO, Agrify, MindMed, KetamineOne ↗

December 15, 2021

Agrify Taps Barry Turkanis To Its Board Of Directors Vertically integrated cannabis company Agrify Corporation (NASDAQ...

Via Benzinga

MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups ↗

December 14, 2021

Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ:

Via Benzinga

Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness ↗

December 13, 2021

Photo by Raimond Klavins

Via Benzinga

North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026

December 14, 2021

Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept...

Via FinancialNewsMedia

Fintech Focus For December 13, 2021 ↗

December 12, 2021

One Big Thing In Fintech: Understanding the fundamentals of a publicly-listed company can help with making more informed investment decisions. Still, many fail in conducting any...

Via Benzinga

EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline ↗

December 10, 2021

This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning...

Via Benzinga

BioMedNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’

December 10, 2021

Via Investor Brand Network

Topics Artificial Intelligence

Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study ↗

December 09, 2021

Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...

Via Benzinga

Topics Derivatives

FDA Shows Support For Development Of MindMed's Session Monitoring System ↗

December 09, 2021

Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) recently met with the US Food and Drug Administration (FDA) Center for Devices and...

Via Benzinga

This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness ↗

December 08, 2021

Photo by Michael Longmire on...

Via Benzinga

MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic’ Data ↗

December 01, 2021

MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant.

Via InvestorPlace

Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds ↗

November 30, 2021

Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective...

Via Benzinga

Psychedelic Drug Stocks Continued To Decline Last Week ↗

November 21, 2021

The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.

Via Talk Markets

3 Psychedelic Stocks for Potential Out-of-This-World Gains ↗

November 18, 2021

Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress.

Via InvestorPlace

Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression

November 23, 2021

Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market....

Via FinancialNewsMedia

MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD ↗

November 16, 2021

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter...

Via Benzinga

Cannabis Movers & Shakers: Mind Medicine, Avant Brands, Delic, Agrify, Ascend Wellness, Pure Beauty ↗

November 11, 2021

Mind Medicine Appoints Maria A. Oquendo To Scientific Advisory Board Psychedelic-focused biotech company Mind Medicine Inc.

Via Benzinga

Topics Cannabis

Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others ↗

November 11, 2021

Compass Pathways reported

Via Talk Markets

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.